SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Lili Boulanger

PatientLili Boulanger
Date of birth2004-08-21
IdentifiersMRN HR-ET025-SYN; SSN (made up) 000-25-7731
Document date2026-04-27
AuthorOdile Marchetti-Rowe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review at week 12, the first maintenance dose of risankizumab. [S]

History of Present Illness

Ms. Boulanger had her third infusion at week 8 and starts maintenance today with the 360 mg on-body injector, which she applied herself in clinic after teaching. Prednisone ended five weeks ago without return of symptoms. The norovirus illness two weeks ago settled in three days. She now has one or two formed stools a day and no pain (Harvey-Bradshaw Index 2). Her liver tests at week 8, drawn with the infusion, were normal, and the final mycobacterial culture was negative at six weeks. Her concert went ahead at the end of March. Her periods have returned. She has regained 3.4 kg since diagnosis. [S]

ElementDetail
Interval changeInduction complete; prednisone stopped five weeks ago; norovirus two weeks ago, resolved
ActivityHarvey-Bradshaw Index 2 (clinical remission)
Week-8 testsLiver enzymes and bilirubin normal
TodayFirst maintenance dose, self-injected; zoster vaccine dose 2
WorkConcert performed; composing again

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; energy good
GastrointestinalNegativeOne or two formed stools a day; no pain or blood
GenitourinaryNegativePeriods returned
MusculoskeletalNegativeNo joint pain
PsychiatricNegativeMood good

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugsOne or two tablets up to every 6 hours as neededOral route2025-12-15activeS
Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect40 mg each morning, tapering by 5 mg weeklyOral route2026-01-28 to 2026-03-24completedS
Risankizumab 600 mg in 10 mL intravenous infusion over at least one hour at weeks 0, 4, and 8 (induction)One infusion every 4 weeks for three dosesIntravenous route2026-02-02 to 2026-04-26completedS
Risankizumab 360 mg in 2.4 mL by subcutaneous on-body injector every 8 weeks (maintenance), from week 12One injection every 8 weeksSubcutaneous route2026-04-27activeS
Ferric derisomaltose 1000 mg in 10 mL intravenous infusion, single doseSingle infusionIntravenous route2026-02-02 to 2026-02-02completedS
Cholecalciferol (vitamin D3) 2000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-01-28activeS
Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisoneOne tablet daily with foodOral route2026-01-28 to 2026-03-24completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-27Body height160cmS
2026-04-27Body weight48.4kgS
2026-04-27Body mass index (BMI) [Ratio]18.9kg/m2S
2026-04-27Systolic blood pressure106mm[Hg]S
2026-04-27Diastolic blood pressure68mm[Hg]S
2026-04-27Heart rate76/minS
2026-04-27Respiratory rate14/minS
2026-04-27Body temperature36.7CelS
2026-04-27Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-27Hemoglobin [Mass/volume] in Blood12.6g/dL12-15.5 g/dLNormalS
2026-04-27MCV [Entitic mean volume] in Red Blood Cells by Automated count83fL80-100 fLNormalS
2026-04-27Ferritin [Mass/volume] in Serum or Plasma86ng/mL15-150 ng/mLNormalS
2026-04-27C reactive protein [Mass/volume] in Serum or Plasma3mg/L<=5 mg/LNormalS
2026-04-27Calprotectin [Mass/mass] in Stool210ug/g<=50 ug/gHighS
2026-04-27Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-04-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L<=33 U/LNormalS
2026-04-27Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L<=32 U/LNormalS
2026-04-27Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL<=1.2 mg/dLNormalS
2026-04-2725-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mL30-100 ng/mLNormalS

Physical Exam

Vital signs recorded on 2026-04-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; BMI 18.9
EyesNo jaundice
AbdomenSoft, non-tender; no mass
SkinInjection site on the abdomen without reaction

Problems

ProblemClinical statusVerificationCodeProvenance
Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settledactiveconfirmed K50.80S — Synthetic diagnosis confirmed within the modern episode; her historical illness is documented (D), but whether it was intestinal tuberculosis or Crohn disease remains a retrospective interpretation (R) and is disputed.
Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging bookedresolvedconfirmed R19.7S — Synthetic presenting concern at the index visit, superseded by the diagnosis; the documented symptoms of early 1915 are echoed (D).
Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9)resolvedconfirmed D50.0S — Synthetic finding at presentation; corrected by intravenous iron.
Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dLactiveconfirmed E44.0S — Synthetic nutritional status at presentation; resolved with treatment and dietitian support.
Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL)resolvedconfirmed E55.9S — Synthetic finding at presentation.
Long-term use of risankizumab, an immunosuppressive biologic, for Crohn diseaseactiveconfirmed Z79.620S — Synthetic treatment status.
Acute norovirus gastroenteritis on risankizumab, with mild dehydration; distinguished from a Crohn flare by the sudden onset, household contacts, and a positive stool PCR; resolved in three daysresolvedconfirmed A08.11S — Synthetic common infection that teaches the difference between infection and a flare in treated Crohn disease; it does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptoms and Harvey-Bradshaw IndexEvery visitCompleted today2: clinical remission, steroid-free
LaboratoryCRPEvery visitCompleted today3 mg/L, normal
LaboratoryFecal calprotectinAbout three months after starting treatmentCompleted today210 ug/g, down from 1240; not yet at target
LaboratoryLiver enzymes and bilirubin during risankizumab inductionThrough at least week 12Completed todayALT 19, AST 21, bilirubin 0.6 today; normal at week 8 with the infusion. Induction monitoring complete; routine checks from now on
LaboratoryHepatitis B antibody after the boosterOne to two months after the doseCompleted todayDrawn today, three months after the booster, after the deviation recorded at week 4: anti-HBs 86 mIU/mL, protective. No harm resulted
LaboratoryHemoglobin, MCV, and ferritinAfter iron, then every 6 to 12 monthsCompleted todayHemoglobin 12.6 g/dL, MCV 83, ferritin 86
LaboratoryVitamin DAfter replacementCompleted today34 ng/mL
LaboratoryAlbumin and weightEvery visitCompleted todayAlbumin 4.1 g/dL; weight 48.4 kg
LaboratoryMycobacterial culture of the biopsiesFinal result at six to eight weeksUp to dateFinal: no growth at six weeks; intestinal tuberculosis excluded
Medication safetyVaccines on biologic therapyAs scheduledCompleted todayRecombinant zoster dose 2 today; no live vaccines
Self-managementSelf-injection teachingAt the first maintenance doseCompleted todayOn-body injector applied by her under supervision
ImagingIleocolonoscopy for endoscopic responseSix to twelve months after starting treatmentDueIn the autumn

Goal progress:

Immunizations given today: Recombinant zoster vaccine, dose 2 of 2 [S]

Guideline basis: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025); STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the IOIBD. Gastroenterology 2021;160:1570-1583 (2021); SKYRIZI (risankizumab-rzaa): prescribing information (Crohn disease dosing; hepatotoxicity monitoring; tuberculosis evaluation; immunizations) (2026)

Follow-up: Risankizumab every 8 weeks at home. Review in three months with CRP and calprotectin. Next scheduled visit 2026-08-03: six-month review on maintenance risankizumab. [S]